Kathryn Kwant

Kathryn Kwant is a research scientist and protein engineer specializing in the development of targeted cancer treatments within the biotechnology industry. She brings over 12 years of domain expertise to the sector, including a continuous five-year tenure operating as a key early scientist at Harpoon Therapeutics. During her time at Harpoon Therapeutics, she focused on engineering proteins with enhanced therapeutic properties, specifically designing bispecific and protease-activated immunotherapies for various oncology applications. Her laboratory research and development efforts have directly contributed to the advancement of multiple cancer drugs that are currently undergoing active clinical trials. Additionally, her technical contributions to the broader field of biotechnology are supported by a portfolio containing multiple patents and pending patent applications. Kwant’s professional background centers on leveraging advanced protein engineering techniques to create novel immunotherapies for complex oncological diseases.